目的 探究生血寶合劑聯(lián)合生血寧片治療妊娠期缺鐵性貧血的臨床療效。方法 選取2013年1月-2016年1月北京市順義區(qū)醫(yī)院就診的妊娠期缺鐵性貧血的婦女126例，根據(jù)隨機(jī)數(shù)表法將全部患者隨機(jī)分為對照組和治療組，每組各63例，對照組患者口服生血寧片，0.5 g/次，2~3次/d；治療組患者在對照組的基礎(chǔ)上口服生血寶合劑，15 mL/次，3次/d。兩組患者均治療3個月。治療后，觀察兩組的臨床療效，比較兩組的血液學(xué)指標(biāo)和不良反應(yīng)情況。結(jié)果 治療后，對照組和治療組的總有效率分別為79.36%、92.06%，兩組比較差異有統(tǒng)計學(xué)意義（P<0.05）；兩組紅細(xì)胞計數(shù)（RBC）、血紅蛋白（Hb）、血清鐵（SI）和鐵蛋白飽和度（TSAT）水平均顯著升高，同組治療前后比較差異有統(tǒng)計學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)的升高程度明顯優(yōu)于對照組，兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）；治療組的不良反應(yīng)總發(fā)生率為7.93%，顯著低于對照組（17.46%），兩組比較差異具有統(tǒng)計學(xué)意義（P<0.05）。結(jié)論 生血寶合劑聯(lián)合生血寧片治療妊娠期缺鐵性貧血患者能夠取得更為優(yōu)異的療效，對患者各項血液學(xué)相關(guān)指標(biāo)水平也有著調(diào)節(jié)作用，在一定程度上能夠降低患者治療過程中出現(xiàn)的不良反應(yīng)發(fā)生率，具有一定的臨床推廣應(yīng)用價值。

Objective To explore Shengxuebao Mistura combined with Shengxuening Tablets in treatment of iron deficiency anemia in pregnancy. Methods A total of 126 pregnant women with iron deficiency anemia were selected in Beijing Shunyi District Hospital from January 2013 to January 2016. According to the random number table method, all patients were randomly divided into control and treatment groups, and each group had 63 cases. Patients in the control group were po administered with Shengxuening Tablets, 0.5 g/time, 2 - 3 times daily. Patients in the treatment group were po administered with Shengxuebao Mistura, 5 mL/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacy was evaluated, and hematology indexes and adverse reactions in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 79.36% and 92.06%, respectively, and there was difference between two groups (P < 0.05). After treatment, the levels of RBC, Hb, SI, and TSAT in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). The observational indexes in the treatment group were significantly higher than those in the control group, with significant difference between two groups (P < 0.05). The incidence rate of adverse reactions in the treatment group was 7.93%, which was significantly lower than 17.46% in the control group, with significant difference between two groups (P < 0.05). Conclusion Shengxuebao Mistura combined with Shengxuening Tablets has more excellent curative effect in treatment of iron deficiency anemia in pregnancy, also has a regulatory role in the levels of various hematology indexes, and can reduce the adverse effects rate, which has a certain clinical application value.